aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

December 15, 2023

https://www.globenewswire.com/news-release/2023/11/13/2778983/0/en/aTyr-Pharma-Presents-Poster-Demonstrating-Preclinical-Effects-of-Efzofitimod-in-Rheumatoid-Arthritis-and-Rheumatoid-Arthritis-Associated-ILD-at-the-ACR-Convergence-2023.html

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster presentation for its lead therapeutic candidate, efzofitimod, at the American College of Rheumatology (ACR) Convergence 2023, which is being held November 10 – 15, 2023, in San Diego, CA.

Read more at globenewswire.com

Related news for (LIFE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.